MedTrace Logo

Prevalence and Incidence of Antibodies Against SARS-CoV-2 Among Primary Healthcare Providers in Belgium (COVID-19)

NCT04779424 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 3390

Last updated 2023-12-04

No results posted yet for this study

Summary

This protocol focuses on the seroprevalence in primary care health care providers (PHCPs) in Belgium.

PHCPs manage the vast majority of COVID-19 and other patients and therefore are essential to organize health care efficiently. Currently however, evidence is lacking on

1. how many PHCPs get infected or diseased in Belgium,
2. the rate at which this happens,
3. their clinical spectrum,
4. their risk factors,
5. the effectiveness of the measures to prevent this from happening and
6. the accuracy of the immunological serology-based point-of-care test in a primary care setting.

This study will be set up as a prospective cohort study. All Belgian GPs in clinical practice will be invited to register online for participation in this national epidemiological study and will be asked to invite the other PHCPs in their practice to do the same. A model and demography-informed sample of registered GPs and other PHCPs will be selected. These participants will be asked at each testing point to perform a capillary blood sample antibody point of care test (OrientGene®) and complete an online questionnaire. All data analysis will be performed and reported after each relevant testing period and at the end of the study.

Conditions

Interventions

OTHER

POCT

Capillary blood sample antibody point of care test

Sponsors & Collaborators

  • Sciensano

    collaborator OTHER_GOV

  • University of Liege

    collaborator OTHER

  • Universiteit Antwerpen

    lead OTHER

Principal Investigators

  • Beatrice Scholtes, MD PhD · University of Liege

  • Elza Duysburgh, MD PhD · Sciensano

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-15
Primary Completion
2021-12-31
Completion
2023-03-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04779424 on ClinicalTrials.gov